围绕阿尔茨海默病（AD）致病物质Aβ的产生和清除开展研究：①揭示神经营养因子受体p75NTR胞外段(p75ECD)拮抗Aβ毒性的生理功能，发现AD脑内p75NTR/p75ECD失衡促进Aβ过度产生；②发现免疫治疗中枢途径清除脑内Aβ伴发的神经损害新机制，证实外周途径清除Aβ的有效性和安全性；③揭示抗氧化基团的Aβ抑聚作用，发现临床抗氧化药物依达拉奉能抑制AD脑内Aβ聚集并促进清除。上述发现为AD防治提供了新思路。以第一/通讯作者在Mol Psychiatry、PNAS、Acta Neuropathol、J Neurosci等发表SCI论文45篇(近5年通讯作者34篇)，IF>10论文4篇，总IF238，被JAMA等他引625次。为Nat Rev Neurol撰写评论和综述，入选科技部中青年科技创新领军人才。下一步拟探讨脑衰老中p75NTR促进AD发生的作用和机制，为AD早期诊治提供切入点。

I have focused my study on the production and clearance of pathogenic amyloid beta (Abeta) in Alzheimer’s disease (AD), I have discovered: 1) the neuroprotective function of the extracellular domain of p75NTR (p75ECD) against Abeta neurotoxicity and the imbalance of the ratio of p75ECD/p75NTR in the brain of AD subjects, which leads to the over-production of Abeta in sporadic AD; 2) the neurotoxic outcome and the underlying mechanism of central immunotherapy-mediated Abeta clearance, together with clarification on the effectiveness and safety of peripheral Abeta clearance and elucidation of physiological Abetaclearance by peripheral organs; 3) that antioxidants suppress the aggregation of Abeta and that the stroke drug edaravone has therapeutic effects for AD by binding Abeta and neutralizing its toxicity. As a first author or corresponding author I have published 45 SCI papers (34 in the last 5 years as a corresponding author) with 4 IF>10 in Molecular Psychiatry, PNAS, Acta Neuropathologica, Journal of Neuroscience, cited 625 times by JAMA, Lancet Neurology etc. I also published comments and reviews invited by Nature Reviews Neurology. I am selected as a Young Talent of Innovation Leaders by Minister of Science Technology. I plan to investigate the impact of aging on p75NTR and its roles of p75NTR in the pathogenesis of AD in the aging brain.